The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Japan Vaccine President and Chairman Swap Posts
June 19, 2014
- Fycompa Meets Primary Endpoints in Patients with PGTC Seizures in PIII Study: Eisai
June 19, 2014
- Takeda UC, CD Treatment Entyvio Goes on Sale in US
June 18, 2014
- Selexipag Meets Primary Endpoint in PIII GRIPHON Study: Nippon Shinyaku
June 18, 2014
- Canagliflozin Shows Significant Improvement in Glycemic Control against Placebo in PIII Study: MTPC
June 18, 2014
- Sawai Seeks US Approval for Livalo Generic, Submits ANDA
June 17, 2014
- Takeda to Withdraw US NDA for Anemia Drug, Cancel Deal with Affymax
June 17, 2014
- Meiji Seika Pharma, Fresenius Kabi Japan Terminate Alliance for Generic Drugs
June 17, 2014
- AZ to Shuffle Sales, Marketing Units, Focus on 3 Disease Areas
June 16, 2014
- Meiji Seika Pharma to Acquire Indian Generic Drug Maker Medreich for US$290 Million
June 16, 2014
- Ex-Novartis Employee Suspected of Manipulating the Number of Events in Sub-Analysis
June 13, 2014
- Teijin Now Largest Shareholder of Kyorin Holdings, Owns 19.12% Stake
June 13, 2014
- Takeda Debuts Aspirin-PPI Combination Drug Takelda in Japan
June 13, 2014
- Valeant Wins US Approval for Kaken’s Onychomycosis Drug
June 12, 2014
- Daiichi Sankyo Initiates Development of Novel, Versatile Vaccine Adjuvant
June 12, 2014
- Nippon Shinyaku to Concentrate Sales Force in Three Therapeutic Fields
June 11, 2014
- PII Study of Novel AD Treatment Begins in Japan: Fujifilm Holdings
June 11, 2014
- Novartis Pharma Collects Adverse Events of 10,000 Patients in Wake of Unreported ADRs in SIGN Trial
June 10, 2014
- Nippon Kayaku to Deploy RA Reps for Remicade Biosimilar
June 9, 2014
- April Ethical Drug Sales Down 3.5%, Hurt by Pullback from Pre-Tax Hike Demand: Crecon Report
June 9, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…